Overweight and obesity
Conditions
Brief summary
Relative change in body weight, Achievement of ≥ 5% weight reduction
Detailed description
Achievement of ≥ 20% weight reduction, Achievement of ≥ 25% weight reduction, Achievement of ≥ 30% weight reduction, Relative change in body weight, Change in waist circumference, Change in systolic blood pressure (SBP), Change in Impact of Weight on Quality Of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function score, Change in SF-36 V2 Health Survey Acute (SF-36v2) Physical Functioning score, Number of Treatment-emergent Adverse Events (TEAEs), Number of Treatment-emergent Serious adverse events (TESAEs)
Interventions
None listed
Sponsors
Novo Nordisk A/S
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relative change in body weight, Achievement of ≥ 5% weight reduction | — |
Secondary
| Measure | Time frame |
|---|---|
| Achievement of ≥ 20% weight reduction, Achievement of ≥ 25% weight reduction, Achievement of ≥ 30% weight reduction, Relative change in body weight, Change in waist circumference, Change in systolic blood pressure (SBP), Change in Impact of Weight on Quality Of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function score, Change in SF-36 V2 Health Survey Acute (SF-36v2) Physical Functioning score, Number of Treatment-emergent Adverse Events (TEAEs), Number of Treatment-emergent Serious adverse events (TESAEs) | — |
Countries
Belgium, Bulgaria, Denmark, Finland, France, Germany, Italy, Netherlands, Poland, Spain
Outcome results
None listed